Lupus Diagnostic and Monitoring Technology
Project Number:
AGN-01-06
Patent Number:
6,030,773
Inventor:
The technology is from the research efforts of Dr. Vincent Agnello of Lahey Clinic, a physician-led, nonprofit group practice teaching hospital affiliated with Tufts University School of Medicine. CTT has an exclusive worldwide agreement to represent and commercialize this laboratory test technology.
Description:
This technology is a patented laboratory test used to diagnose and monitor Systemic Lupus Erythematosus (SLE). SLE, commonly called "Lupus," is an autoimmune disease characterized by the appearance in serum of antibodies directed against a number of "self" antigens. This disease currently affects approximately 1.5 million patients in the United States.
Advantages:
The solid-phase assay significantly improves the detection of antibodies specifically directed towards dsDNA in serum with unparalleled sensitivity and precision compared to existing diagnostic methods that detect and have difficulty separating both ssDNA and dsDNA. The assay is adaptable to operate on commercially available chemiluminescence detection platforms and has extensive clinical data from the more than 10,000 assays performed at the Lahey Clinic.
This is a cost effective, scalable testing platform for the early detection of Lupus as well as the monitoring of therapeutic efficacy and flares.
Applications:
Potential market opportunities include medical kit manufacturers for both diagnosis and treatment of Lupus.
For more information please contact:
Johnnie D. Johnson
Chief Executive Officer
Competitive Technologies, Inc.
This email address is protected, Javascript must be enabled to view it
Tel: 203.368.6044
